Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Medusa Pharmaceuticals
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary<ref name=":0">Source: the company.</ref> == Medusa Pharmaceuticals is an Imperial College London spin-out based on a serendipitous discovery: synergy between an aminoglycoside antibiotic and an alkylating agent, able to overcome antimicrobial resistance, treating lethal infections. We are developing a discovery platform to generate a powerful suite of broadly targeting combination therapeutics optimised to treat WHO priority pathogens including: P. aeruginosa and M. tuberculosis. Our strategy repurposes approved drugs, leveraging decades of R&D, overcoming the cost and regulatory hurdles associated with bringing entirely new antibiotics to market. Combat AMR to treat the untreatable, saving lives all around the world. Seeking to raise £500k for a 2-year runway enabling a postdoctoral researcher to conduct fundamental early research in Dr Peter Sarkies’ Imperial College lab.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)